AI documentation built for oncology
Oncology visits are long, complex, and demand meticulous documentation — staging, treatment regimens, toxicity assessments, response evaluations, and survivorship planning. Eluve captures it all from the conversation so you can focus on your patients instead of your chart.
75%
less time charting
2 min
average note turnaround
99%
documentation accuracy
Built for your workflow
Ambient Oncology Notes
Eluve listens to your patient encounter and generates structured visit notes — chief complaint, interval history, review of systems, physical examination, assessment with staging, and a detailed treatment plan — without you typing a word.
Auto Billing & Coding
CPT codes for E/M visits, chemotherapy administration (96413-96417), therapeutic injections, and drug HCPCS codes are suggested automatically based on the encounter. ICD-10 codes capture tumor site, laterality, and encounter type so claims go out right the first time.
Treatment Plan Documentation
Structured treatment plans including regimen name, cycle number, dose modifications, and anticipated schedule are generated from the visit. Intent of therapy — curative, adjuvant, neoadjuvant, or palliative — is documented clearly for every patient.
Toxicity & Response Tracking
Adverse events discussed during the visit are documented with CTCAE grading. Imaging response is captured using RECIST criteria language — complete response, partial response, stable disease, or progressive disease — keeping your notes audit-ready.
Referral & Coordination Letters
Letters to referring physicians, radiation oncology, surgical oncology, palliative care, and other specialists are drafted automatically from the encounter — with diagnosis, staging, treatment history, and current plan included.
Medication & Regimen Summaries
Oral chemotherapy prescriptions, supportive medications, anti-emetics, growth factors, and dose adjustments discussed during the visit are captured automatically. Generates patient-friendly summaries with dosing schedules and side effects to watch for.
Every oncology visit type, one AI scribe
Oncology spans initial consultations to survivorship and everything in between. Eluve handles all of them with specialty-tuned documentation.
New Patient Consultation
Comprehensive evaluation with staging review, molecular profiling, treatment planning, and goals-of-care discussion
Chemotherapy Follow-Up
Pre-cycle assessment including toxicity review, labs, dose modifications, and treatment continuation decisions
Immunotherapy Visit
Immune checkpoint inhibitor administration with immune-related adverse event monitoring and response assessment
Infusion Suite Visit
Chemotherapy, immunotherapy, and supportive infusion documentation with drug timing, premedications, and reactions
Restaging & Response
Imaging review, RECIST response assessment, tumor marker trending, and treatment continuation or change decisions
Survivorship Visit
Post-treatment surveillance with late-effects monitoring, screening recommendations, and survivorship care plan updates
Palliative & Supportive Care
Symptom management, goals-of-care conversations, advance directive discussions, and hospice referral planning
Tumor Board Prep
Case summaries for multidisciplinary tumor board with diagnosis, staging, imaging, pathology, and treatment options
Second Opinion
Comprehensive record review and independent treatment recommendation with rationale for alternative approaches
Oral Chemotherapy Management
Oral oncolytic prescribing, adherence monitoring, toxicity assessment, and dose adjustment documentation
How an oncology visit works with Eluve
Treatment history at your fingertips
Eluve compiles the patient's cancer diagnosis, staging, treatment regimen, most recent labs (CBC, CMP, tumor markers), imaging results, and prior toxicities into a concise pre-visit summary. You walk into the room knowing exactly where the patient stands in their treatment course.
You talk with your patient, Eluve documents
Focus on the conversation — symptom review, toxicity assessment, treatment response discussion, and shared decision-making. Eluve captures everything in the background and generates a structured oncology note with interval history, systems review, examination findings, assessment with current disease status, and the plan for next cycle or treatment change.
Notes, orders, and letters — done
Review your completed visit note, confirm suggested CPT and ICD-10 codes, generate letters to the referring physician or multidisciplinary team, and update the treatment plan — all from the same encounter. Chemotherapy administration codes, drug HCPCS codes, and infusion times are pre-populated. Sign off in under a minute.
Better documentation means fewer denied claims and more captured revenue
Oncology billing is high-value and high-complexity. The gap between what you do and what your notes support costs cancer practices hundreds of thousands per year.
More
complete documentation per visit
When the ambient scribe captures the full encounter — every condition addressed, every clinical decision, every procedure — your documentation supports the true complexity of each visit without extra work.
Fewer
denied claims
Documentation that captures the clinical reasoning, medical necessity, and payer-specific detail from the start means fewer gaps for payers to deny on — and less time spent on appeals.
3x
More complete treatment documentation
When documentation captures every drug administered, every toxicity discussed, and every treatment decision made, practices see dramatically more complete records — supporting both billing accuracy and quality reporting.
3 hrs
Saved per clinician per day
Less time on notes, referral letters, prior authorizations, and coding means you leave the clinic on time — or see the extra patients who need you.
If your practice gets audited, your notes are ready
Oncology billing draws frequent payer scrutiny due to high-value claims. Eluve structures every note so it holds up under audit.
Chemotherapy Administration Accuracy
Every infusion is documented with drug names, doses, routes, start/stop times, and billing hierarchy sequencing. Auditors see exactly what was administered and why it was coded the way it was.
Medical Necessity Documentation
Treatment rationale is linked to diagnosis, staging, biomarkers, and guideline references. When a payer asks why you chose this regimen, the answer is already in the note.
Quality Measure Reporting
Eluve captures the discrete data points that MIPS oncology measures require — including staging documentation, treatment intent, pain assessment, and advance care planning discussions — so you're not scrambling at reporting time.
Clinical Trial Documentation
For patients on clinical trials, Eluve separates standard-of-care documentation from investigational protocol activities — helping ensure proper billing and avoiding coverage analysis errors.
HIPAA-Compliant by Default
All data is encrypted in transit and at rest. Eluve is SOC 2 Type II certified and operates under a BAA with every practice. Your patient data is never used to train AI models.
See what Eluve generates
Every clinic is different. Switch between note styles to see how Eluve adapts to your preferred level of detail.
New Patient Oncology Consultation
Reason for Consultation
Newly diagnosed non-small cell lung cancer, referred by Dr. Martin (Pulmonology) for medical oncology evaluation and treatment planning.
History of Present Illness
67-year-old male, former smoker (30 pack-year history, quit 8 years ago), presenting with a 6-week history of persistent cough, mild hemoptysis, and unintentional 12-lb weight loss over 3 months. Chest CT identified a 4.8 cm right upper lobe mass with ipsilateral mediastinal lymphadenopathy. PET/CT showed FDG-avid right upper lobe mass (SUVmax 14.2) and FDG-avid right paratracheal and subcarinal lymph nodes (SUVmax 8.6). No distant metastases identified. Brain MRI negative. Bronchoscopic biopsy confirmed adenocarcinoma of the lung. Molecular testing: EGFR wild-type, ALK-negative, ROS1-negative, PD-L1 TPS 65%, KRAS G12C mutation detected. No actionable BRAF, MET, RET, or NTRK alterations.
Past Medical History
COPD (moderate, on tiotropium), hypertension, type 2 diabetes (HbA1c 7.1%), hyperlipidemia. No prior malignancies. No prior chest radiation.
Surgical History
Cholecystectomy (2012). No thoracic surgery.
Medications
Tiotropium 18 mcg inhaled daily, lisinopril 20 mg daily, metformin 1000 mg BID, atorvastatin 40 mg daily, aspirin 81 mg daily.
Social History
Former smoker, quit 2018 (30 pack-years). No alcohol abuse. Retired electrician. Lives with wife. Good functional status — ECOG performance status 1. Independent in all ADLs.
Physical Examination
Vitals: BP 134/82, HR 76, Temp 36.9°C, SpO2 94% RA, Weight 78.4 kg, Height 178 cm. General: Well-developed, appears stated age, no acute distress. HENT: No cervical or supraclavicular lymphadenopathy. Lungs: Decreased breath sounds right upper zone. No wheezes or crackles. Cardiovascular: Regular rate and rhythm, no murmurs. Abdomen: Soft, non-tender, no hepatomegaly. Extremities: No clubbing, cyanosis, or edema. Neuro: Alert and oriented, no focal deficits.
Staging
Non-small cell lung cancer (adenocarcinoma), right upper lobe. AJCC 8th edition: cT2bN2M0, Stage IIIA. Molecular: EGFR WT, ALK-neg, ROS1-neg, PD-L1 TPS 65%, KRAS G12C+. ECOG PS: 1.
Assessment & Plan
67-year-old male with newly diagnosed Stage IIIA (cT2bN2M0) NSCLC adenocarcinoma. Tumor is PD-L1 high (65%), KRAS G12C mutated, with no targetable driver mutations amenable to first-line TKI therapy. 1. Recommend concurrent chemoradiation with carboplatin AUC 2 + paclitaxel 45 mg/m2 weekly x 6 weeks with concurrent definitive thoracic radiation (60 Gy in 30 fractions) per NCCN guidelines for unresectable Stage IIIA 2. Followed by durvalumab 10 mg/kg q2 weeks x 12 months consolidation (per PACIFIC trial data), given PD-L1 >= 1% 3. Case to be presented at multidisciplinary tumor board this Thursday for surgical oncology and radiation oncology input on resectability 4. Pre-treatment workup: PFTs, baseline echocardiogram, CBC, CMP, LDH 5. Refer to radiation oncology for simulation and treatment planning 6. Discussed diagnosis, staging, prognosis, treatment options, goals of care, and expected side effects at length with patient and wife. Patient expresses understanding and wishes to proceed with curative-intent treatment 7. Smoking cessation reinforced — patient committed to remaining abstinent 8. Return in 1 week to review tumor board recommendation and initiate treatment
Generated from a 45-minute new patient oncology consultation
Frequently asked questions
Yes. Eluve is purpose-built for oncology workflows and understands the specialty's unique terminology, documentation standards, and clinical complexity. It recognizes AJCC/TNM staging, NCCN guideline references, molecular marker terminology, and regimen-specific language — generating notes that match how oncologists actually document treatment plans and clinical encounters.
Eluve captures the full treatment context from each encounter — regimen name, cycle number, drug doses, dose modifications, treatment intent, and response assessments using RECIST criteria. Staging details including TNM classification, biomarker results, and molecular profiling are documented with the specificity that payers and clinical trial eligibility reviews require.
Yes. Eluve documents treatment-related adverse events with CTCAE grading when discussed during the visit, including the specific toxicity, its severity grade, and any dose modifications or supportive care changes made in response. This structured toxicity documentation supports both clinical decision-making and the medical necessity rationale that payers require for ongoing treatment authorization.
Yes. Eluve is trained on oncology encounters and recognizes cancer-specific workflows including chemotherapy follow-ups, new patient consultations, treatment planning visits, toxicity assessments, survivorship care, and tumor board discussions. It understands staging systems (AJCC/TNM), RECIST response criteria, CTCAE grading, molecular markers, and regimen-specific terminology.
Yes. Eluve captures regimen details including drug names, doses, cycle numbers, dose modifications, and schedule changes discussed during the visit. Whether your patient is on single-agent immunotherapy or a multi-drug combination like FOLFOX or R-CHOP, the documentation reflects the exact treatment plan.
Yes. Eluve suggests E/M codes, chemotherapy administration codes (96413-96417), therapeutic injection codes, hydration codes, and drug-specific HCPCS codes based on what was documented during the encounter. ICD-10 codes are mapped to the specific tumor site, laterality, and whether the encounter is for active treatment (Z51.11, Z51.12) or surveillance.
Eluve captures imaging response using RECIST-aligned language (complete response, partial response, stable disease, progressive disease) and documents treatment-related adverse events with CTCAE grading when discussed during the visit. This structured documentation supports clinical trial eligibility assessments and insurance authorizations.
Yes. For patients completing active treatment, Eluve generates structured survivorship care plans that include cancer and treatment summary, recommended surveillance schedule, long-term and late effects to monitor, and health maintenance recommendations — following ASCO and NCCN survivorship guidelines.
Eluve is HIPAA compliant and SOC 2 Type II certified. All data is encrypted in transit and at rest. We offer a Business Associate Agreement (BAA) for every practice. Your data is never used to train AI models.
Most oncology practices are up and running within a day. Eluve integrates with your existing EHR — including oncology-specific systems like Flatiron OncoEMR and iKnowMed — and your team can start using it immediately with no workflow disruption.
Yes. Eluve is designed for busy oncology practices and infusion suites seeing dozens of patients per day per provider. Notes are generated in real time so documentation never falls behind, even on your heaviest infusion days.
Ready to focus on your patients, not your charts?
Join oncologists who have eliminated after-hours charting, documentation backlogs, and billing headaches with Eluve.
Request a Demo